title: Heart failure years after cancer treatment.
abstract: Progress in cancer treatment has significantly improved survival of patients with cancer. However, the incidence of cardiovascular diseases such as left ventricular dysfunction (LVD) and chronic heart failure (HF) is increasing due to the long-term toxic effects of chemotherapy and radiotherapy. Cardio-oncology teams are necessary to ensure the implementation of primary prevention strategies and screening protocols for early recognition of LVD. Moreover, early administration of advanced treatment for HF is crucial to achieve left ventricular recovery. In this article we will focus on the prevalence of chronic HF among cancer survivors, the main risk factors of LVD and chronic HF, the prevention strategies and management based on the current evidence and, finally, the future perspectives in this field.
authors.affiliation: Cardiology Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
authors.forename: Nieves
authors.initials: N
authors.lastname: Montoro
authors.affiliation: Cardiology Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: López-Sendón
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D066126:Cardiotoxicity / Q000453:epidemiology / Q000517:prevention & control; D002908:Chronic Disease; D006333:Heart Failure / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D015995:Prevalence; D012307:Risk Factors; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000453:epidemiology* / Q000517:prevention & control
chemical_list: D000970:Antineoplastic Agents
keywords: cardiotoxicity; heart failure; left ventricular dysfunction